In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (NASDAQ:AZN) revealed ...

AstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

One of those trials of the drug, called AZD5004, will focus on reduction in body weight on average in obese and overweight ...

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...

After AstraZeneca (AZN) presented data at the ObesityWeek conference, Deutsche Bank said the company’s oral small molecule GLP1 drug ...

AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The Anglo ...

Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is ...

Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca (AZN – Research Report) and keeping the price ...

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.